.png){kind=icon}
返回
Aeroallergen immunotherapy update: Developments since the third Practice Parameter
.png){kind=icon}
PRE
AI
DOI：10.2500/aap.2025.46.250067.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Background: Allergy immunotherapy is a proven treatment for allergic rhinitis and asthma with the potential to modify the natural history of these disorders. Considerable advances have been seen in the past 15 years since publication of the third update of the Allergen Immunotherapy Practice Parameter. Objective: The aim was to understand new developments that pertain to subcutaneous immunotherapy and sublingual immunotherapy (SLIT). Methods: New evidence related to advances related to efficacy and safety of allergy immunotherapy are presented as well as unmet needs and future directions. Results: Most new evidence has come from large double-blind placebo controlled trials of SLIT tablets, which better define efficacy and safety in patients with allergic rhinitis, allergic asthma, and atopic dermatitis. More evidence has emerged that identifies risk factors for anaphylaxis to subcutaneous injections and approaches to mitigate risk. Conclusion: Two modalities of allergy immunotherapy are available to allergy specialists. Both SLIT and subcutaneous immunotherapy have near equivalent efficacy, but SLIT has a superior safety profile, allowing self-administration.
Keyword:
ALLERGEN IMMUNOTHERAPY
SUBCUTANEOUS IMMUNOTHERAPY
NONFATAL REACTIONS
FATAL REACTIONS
RISK-FACTORS
TABLET
EFFICACY
SAFETY
期刊
A
IF:
2.2
论文数:
55
被引数:
0
机构
引用论文
.png){kind=icon}
Long-term real-world effectiveness of allergy immunotherapy in patients with allergic rhinitis and asthma: Results from the REACT study, a retrospective cohort study过敏性鼻炎和哮喘患者过敏免疫治疗的长期实际效果: REACT研究的结果，一项回顾性队列研究
OAAI
OAAI分享收藏
分享收藏
查看更多内容